Abrégé

Embodiments of the present disclosure concern administration of a cell population to an individual for regeneration of a tissue. The cell population may comprise fibroblasts and/or immune cells, either of which may be modified or unmodified. The tissue for regeneration may be a thymus.

Classes IPC  ?

• A61K 35/33 - Fibroblastes
• A61K 40/00 - Immunothérapie cellulaire
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

The present disclosure provides methods, compositions, and systems for producing and using organoids comprising fibroblasts. The organoids can be generated and placed in a particular storage matrix which allows for sufficient conditions for transport and reduces damage to cells in the organoids compared to known media. The organoids may be utilized for extended release of the fibroblasts for cell therapy and also for drug delivery at a target site following administration to an individual in need thereof.

Classes IPC  ?

• A61K 35/33 - Fibroblastes
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

The present disclosure provides methods, compositions, and systems for producing and using organoids comprising fibroblasts. The organoids can be generated and placed in a particular storage matrix which allows for sufficient conditions for transport and reduces damage to cells in the organoids compared to known media. The organoids may be utilized for extended release of the fibroblasts for cell therapy and also for drug delivery at a target site following administration to an individual in need thereof.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• A61K 35/33 - Fibroblastes
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet

Abrégé

Embodiments of the present disclosure concern administration of a cell population to an individual for regeneration of a tissue. The cell population may comprise fibroblasts and/or immune cells, either of which may be modified or unmodified. The tissue for regeneration may be a thymus.

Classes IPC  ?

• A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Abrégé

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.

Classes IPC  ?

• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61P 35/00 - Agents anticancéreux
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.

Classes IPC  ?

• A61K 35/33 - Fibroblastes
• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.

Classes IPC  ?

• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61P 35/00 - Agents anticancéreux
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus